IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) Meeting Abstract
| Authors: | Powles, T.; McDermott, D. F.; Rini, B.; Motzer, R. J.; Atkins, M. B.; Fong, L.; Joseph, R. W.; Pal, S. K.; Ravaud, A.; Bracarda, S.; Suarez Rodriguez, C.; Maio, M.; Gore, M.; Grünwald, V.; Staehler, M.; Qiu, J.; Thobhani, A.; Huseni, M.; Schiff, C.; Escudier, B. |
| Abstract Title: | IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) |
| Meeting Title: | 42nd ESMO Congress (ESMO 2017) |
| Journal Title: | Annals of Oncology |
| Volume: | 28 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2017 Sep 8-12 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2017-09-01 |
| Start Page: | mdx440.033 |
| Language: | English |
| ACCESSION: | WOS:000411324005093 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdx440.033 |
| Notes: | Meeting Abstract: LBA39 -- Appears on page 624 of the abstract book -- Source: Wos |
